European Archives - Page 674 of 1134 - European Medical Journal

The metrics of medical affairs

Measuring the impact of medical affairs is less straightforward than it is for R&D or commercial, but we must establish success metrics.

Creating brand loyalty with RWE

The commercial value of RWE is yet to be realised, but the benefits extend far beyond the aisles in which it is currently in high demand.

Calling checkmate on meaningless social media

The pharma industry is dabbling in the game of social media, and it’s no secret that they need to have a better presence on these platforms.

Digital therapeutics: fad or force for change?

More and more digital therapeutics are hitting the market, taking the patient experience of healthcare into a more innovative, less invasive place, but are these digital devices worth the hype?

Talking to Dr Gino Martini

Dr Gino Martini, Chief Scientist, Royal Pharmaceutical Society, covers the rapid data generation of COVID-19, the value of digital for HCPs, and why he thinks there will be much to reflect on after the pandemic has passed.

Newborn Screening: Now and in the Future

WHAT is the value of newborn screening (NBS) to the rare diseases community?…

Driving Care Pathways into the Future

ARTIFICIAL intelligence could one day form the backbone of healthcare, but with such a powerful technology looming on our horizon, what exactly does…

Disruptive Innovations in Clinical Research

New trends in clinical research and trial design were discussed, as well as challenges associated with the need to perform innovatively to advance…

Early Intervention with Anti-Tumour Necrosis Factor in Ulcerative Colitis: The Missing Piece of The Puzzle?

In an interactive symposium moderated by Dr Cummings, the question: “Is early intervention with anti-TNF the key to achieving long-lasting remission…

EMJ 5.2 2020

Welcome to EMJ 5.2! Our latest edition of EMJ highlights the experiences of patients with rare diseases, and the clinicians and organisations working…